ES2258869T3 - Particulas similares a virus para la induccion de autoanticuerpos. - Google Patents

Particulas similares a virus para la induccion de autoanticuerpos.

Info

Publication number
ES2258869T3
ES2258869T3 ES99970772T ES99970772T ES2258869T3 ES 2258869 T3 ES2258869 T3 ES 2258869T3 ES 99970772 T ES99970772 T ES 99970772T ES 99970772 T ES99970772 T ES 99970772T ES 2258869 T3 ES2258869 T3 ES 2258869T3
Authority
ES
Spain
Prior art keywords
ccr5
vlp
protein
cells
tolerogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99970772T
Other languages
English (en)
Spanish (es)
Inventor
John T. Schiller
Bryce Chackerian
Douglas R. Lowy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22304219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2258869(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2258869T3 publication Critical patent/ES2258869T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
ES99970772T 1998-10-21 1999-10-20 Particulas similares a virus para la induccion de autoanticuerpos. Expired - Lifetime ES2258869T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10513298P 1998-10-21 1998-10-21
US105132P 1998-10-21

Publications (1)

Publication Number Publication Date
ES2258869T3 true ES2258869T3 (es) 2006-09-01

Family

ID=22304219

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99970772T Expired - Lifetime ES2258869T3 (es) 1998-10-21 1999-10-20 Particulas similares a virus para la induccion de autoanticuerpos.

Country Status (9)

Country Link
US (5) US6719978B2 (enExample)
EP (1) EP1123114B1 (enExample)
JP (1) JP4486257B2 (enExample)
AT (1) ATE314095T1 (enExample)
AU (1) AU770802B2 (enExample)
CA (1) CA2347411C (enExample)
DE (1) DE69929232T2 (enExample)
ES (1) ES2258869T3 (enExample)
WO (1) WO2000023955A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
JP4486257B2 (ja) * 1998-10-21 2010-06-23 アメリカ合衆国 自己抗体の誘導のためのウイルス様粒子
WO2000032227A2 (en) * 1998-11-30 2000-06-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
AU2007202761B2 (en) * 2001-01-19 2010-01-21 Kuros Biosciences Ag Molecular antigen array
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
FR2828404B1 (fr) * 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
ES2335979T3 (es) 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
RU2350622C2 (ru) * 2001-10-05 2009-03-27 Цитос Байотекнолоджи Аг Конъюгат ангиотензиновой пептидной составляющей с носителем, композиция вакцины, способ иммунизации животного и способ лечения или профилактики физического нарушения, ассоциированного с активируемой ренином ангиотензиновой системой
MXPA04002644A (es) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Conjugados que portan un peptido de angiotensina y usos de los mismos.
AU2002362696B2 (en) * 2001-10-05 2008-05-29 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
NZ532516A (en) * 2001-11-07 2008-05-30 Cytos Biotechnology Ag Antigen arrays presenting IL-5, IL-13 or eotaxin for treatment of allergic eosinophilic diseases
RU2322258C2 (ru) * 2001-11-07 2008-04-20 Цитос Байотекнолоджи Аг Антигенные матрицы для лечения заболевания костей
RU2319503C2 (ru) * 2001-11-07 2008-03-20 Цитос Байотекнолоджи Аг Композиция для иммунизации (варианты), способ ее получения и применение для лечения аллергических эозинофильных заболеваний
ATE412428T1 (de) * 2001-11-07 2008-11-15 Cytos Biotechnology Ag Antigen-raster enthaltend rankl zur behandlung von knochenerkrankungen
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
WO2003103605A2 (en) * 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
CN102061288A (zh) 2002-07-17 2011-05-18 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
IN2008CN05409A (enExample) 2002-07-18 2015-10-02 Cytos Biotechnology Ag
CA2492930C (en) * 2002-07-19 2013-01-08 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
WO2004032622A2 (en) * 2002-09-03 2004-04-22 Large Scale Biology Corporation Production of peptides in plants as viral coat protein fusions
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
CA2517839A1 (en) * 2003-03-26 2004-10-07 Martin F. Bachmann Melan-a peptide analogue-virus-like-particle conjugates
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
WO2005005614A2 (en) * 2003-07-03 2005-01-20 Pecos Labs, Inc. Combined b-cell and t-cell epitopes on vlp for improved vaccines
AU2005205181A1 (en) * 2004-01-20 2005-07-28 Cytos Biotechnology Ag Particle-induced ghrelin immune response
WO2005091753A2 (en) * 2004-03-25 2005-10-06 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
EP1751186A2 (en) * 2004-06-02 2007-02-14 Cytos Biotechnology AG Carrier conjugates of tnf-peptides
KR20070058426A (ko) * 2004-06-02 2007-06-08 사이토스 바이오테크놀로지 아게 비-인간 ｔｎｆ-펩티드의 담체 콘쥬게이트의 의학적 용도
DE102004036913A1 (de) * 2004-07-16 2006-02-09 Responsif Gmbh Verwendung von Pentameren zur Herstellung eines Medikaments
KR20070059207A (ko) 2004-10-05 2007-06-11 사이토스 바이오테크놀로지 아게 Ｖｌｐ-항원 컨쥬게이트 및 백신으로서 그의 용도
JP2008517975A (ja) 2004-10-25 2008-05-29 サイトス バイオテクノロジー アーゲー 胃酸分泌抑制ポリペプチド（ｇｉｐ）抗原アッセイ及びその使用
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
NZ561040A (en) * 2005-03-18 2009-04-30 Cytos Biotechnology Ag Cat allergen fusion proteins and use thereof
LT5414B (lt) 2005-04-13 2007-04-25 Biotechnologijos Institutas Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu
AU2006259057A1 (en) * 2005-06-14 2006-12-21 Cytos Biotechnology Ag Antigen conjugates and uses thereof
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
CA2621466A1 (en) * 2005-09-08 2007-04-05 Kentucky Bioprocessing, Llc Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications
RU2441067C2 (ru) * 2005-09-28 2012-01-27 Цитос Биотехнологи Аг Конъюгаты интерлейкина-1 и их применение
CA2636139A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
EP2530086B1 (en) 2006-06-12 2019-03-20 Kuros Biosciences AG Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
CA2671873C (en) 2006-12-12 2018-10-09 Brian Stephen Sproat Oligonucleotides containing high concentrations of guanine monomers
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
ES2602610T3 (es) * 2007-05-31 2017-02-21 Medigene Ag Proteína estructural mutada de un parvovirus
WO2009009430A1 (en) * 2007-07-06 2009-01-15 University Of Louisville Research Foundation, Inc. Diagnosing and protecting horses against papillomavirus
EP2062592A1 (en) 2007-11-20 2009-05-27 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten System for delivery into a XCR1 positive cell and uses thereof
AU2009325950B2 (en) 2008-12-09 2013-03-07 Pfizer Vaccines Llc IgE CH3 peptide vaccine
RU2518291C2 (ru) 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Антигенные tau-пептиды и их применения
EP3358008A1 (en) 2009-09-03 2018-08-08 Pfizer Vaccines LLC Pcsk9 vaccine
WO2011033493A1 (en) 2009-09-21 2011-03-24 Conservatoire National des Arts et Métiers Carrier conjugates of il-23-peptides and their induced antibodies
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US9821043B2 (en) * 2011-09-15 2017-11-21 Medigene Ag Anti-HER2 vaccine based upon AAV derived multimeric structures
EP2948469A4 (en) 2013-01-23 2016-11-02 Univ Leland Stanford Junior STABILIZED HEPATITIS B CORE POLYPEPTIDE
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
DK3368068T3 (da) 2015-10-30 2021-02-22 Univ Copenhagen Viruslignende partikler med effektiv epitopdisplay
AU2019255370B2 (en) 2018-04-19 2023-11-02 Checkmate Pharmaceuticals, Inc. Synthetic RIG-I-like receptor agonists
CN115279905A (zh) 2019-10-23 2022-11-01 里珍纳龙药品有限公司 合成rig-i样受体激动剂
WO2022140655A1 (en) * 2020-12-23 2022-06-30 The Trustees Of Columbia University In The City Of New York Single-molecule electronic multiplex nanopore immunoassays for biomarker detection
US20250332278A1 (en) * 2022-06-01 2025-10-30 The Regents Of The University Of California Multivalent display of apoai peptide on nanoparticles against atherosclerosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
GB8903313D0 (en) 1989-02-14 1989-04-05 Wellcome Found Conjugates
US5714374A (en) * 1990-09-12 1998-02-03 Rutgers University Chimeric rhinoviruses
GB9114003D0 (en) * 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
JPH0519914A (ja) * 1991-07-17 1993-01-29 Sharp Corp 半導体装置の内部降圧回路
KR940008286B1 (ko) * 1991-08-19 1994-09-09 삼성전자 주식회사 내부전원발생회로
CH684782A5 (de) 1992-01-27 1994-12-30 Rolf M Zinkernagel C O Inst Fu Antigen zur Auslösung von CD8+ Zellimmunantworten.
KR950008453B1 (ko) * 1992-03-31 1995-07-31 삼성전자주식회사 내부전원전압 발생회로
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
CA2145063A1 (en) 1992-09-22 1994-03-31 Cambridge Genetics Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5721485A (en) * 1996-01-04 1998-02-24 Ibm Corporation High performance on-chip voltage regulator designs
EP0927044A4 (en) 1996-04-16 1999-09-08 Immusol Inc DEFINED TARGET VIRAL VECTORS
KR100224669B1 (ko) * 1996-12-10 1999-10-15 윤종용 내부 전원 전압 발생기 회로
US6171591B1 (en) * 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
JPH11231954A (ja) * 1998-02-16 1999-08-27 Mitsubishi Electric Corp 内部電源電圧発生回路
DE19827457C1 (de) * 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
EP0994403B1 (en) * 1998-10-15 2003-05-21 Lucent Technologies Inc. Current mirror
JP4486257B2 (ja) * 1998-10-21 2010-06-23 アメリカ合衆国 自己抗体の誘導のためのウイルス様粒子
WO2000032227A2 (en) 1998-11-30 2000-06-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
US6373754B1 (en) * 2000-07-17 2002-04-16 Samsung Electronics Co., Ltd. Semiconductor memory device having stable internal supply voltage driver
US20060210687A1 (en) * 2002-11-06 2006-09-21 Fiberstar, Inc. Enhanced crackers, chips, wafers and unleavened using highly refined cellulose fiber ingredients

Also Published As

Publication number Publication date
DE69929232D1 (de) 2006-02-02
US7479280B2 (en) 2009-01-20
AU770802B2 (en) 2004-03-04
US20080175853A1 (en) 2008-07-24
AU1214300A (en) 2000-05-08
WO2000023955A8 (en) 2000-06-22
EP1123114A1 (en) 2001-08-16
US20030072753A1 (en) 2003-04-17
JP2002528393A (ja) 2002-09-03
JP4486257B2 (ja) 2010-06-23
US20020081295A1 (en) 2002-06-27
US7875450B2 (en) 2011-01-25
US20040228798A1 (en) 2004-11-18
ATE314095T1 (de) 2006-01-15
CA2347411A1 (en) 2000-04-27
US6719978B2 (en) 2004-04-13
WO2000023955A1 (en) 2000-04-27
EP1123114B1 (en) 2005-12-28
US7371572B2 (en) 2008-05-13
CA2347411C (en) 2012-04-03
US20060210587A1 (en) 2006-09-21
DE69929232T2 (de) 2006-08-31

Similar Documents

Publication Publication Date Title
ES2258869T3 (es) Particulas similares a virus para la induccion de autoanticuerpos.
ES2213754T3 (es) Particulas quimericas de tipo papilomavirus.
Chackerian et al. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies
ES2301551T3 (es) Moleculas l1 de papilomavirus humano (hpv) quimericas y usos de las mismas.
JP2002528393A5 (enExample)
SG177269A1 (en) Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
US6485728B2 (en) Formalin-Inactivated human papillomavirus L1 protein vaccine
US7691386B2 (en) Chimeric papillomavirus-like particles
Fleury et al. Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications
EP1637166A2 (en) Virus-like particles for the induction of autoantibodies
AU717647B2 (en) Chimeric papillomavirus-like particles
AU717932B2 (en) Chimeric papillomavirus-like particles
Greenstone Chimeric papillomavirus virus-like particles: A biochemical and immunological characterization
Chen Construction of Engineered Nanoparticles with Tailored Densities of Self-Antigen for the Study of B-cell Activation